In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Insmed's current price exceeds its PERT-weighted fair value by 6.5%, indicating potential overvaluation. High confidence in valuation contrasts with severe negative DCF outcomes, while analyst targets suggest significant upside. Financial health is mixed, with strong liquidity and growth but zero profitability and efficiency, implying elevated risk amid growth prospects.